Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New drug application filed for BTG's Oxycodone HCl/Ibuprofen technology

BTG : 10 October, 2006  (New Product)
BTG, the global technology commercialisation company, announced today that Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, has submitted a New Drug Application with the U.S.
Food and Drug Administration to market oxycodone HCl/ibuprofen for the treatment of moderate and severe pain. Oxycodone HCl/ibuprofen, BTGs licensed technology, is a patented combination of oxycodone, a powerful analgesic, and ibuprofen, one of the most widely used and trusted non-steroidal anti-inflammatory drugs.

Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories, stated: 'The filing of this application, based on the technology licensed from BTG, represents an important opportunity for Forest Laboratories in the $2.5 billion analgesic market. Forest has successfully marketed several pain products and we believe that this new analgesic combination which contains an effective dose of oxycodone and the optimal dose of ibuprofen, may be particularly useful where other available analgesics and analgesic combinations do not provide adequate pain relief.'

The oxycodone component, already used to great success in combination with aspirin, has proven effective in treating patients with moderate to severe pain. The new drug is a combination of oxycodone with a well-recognised anti-inflammatory, ibuprofen, which has the potential to be of great benefit to many patients in pain. The potential oxycodone/ibuprofen composition is licensed exclusively to Forest from BTG.

Dr Geoffrey Porges, Executive Vice President, Health, Medical and BioTechnologies at BTG, commented: 'This combination is a potentially important addition to the range of new analgesic agents. We are delighted with the tremendous progress Forest Laboratories has made in reaching this milestone. This product reinforces the commercial success BTG has achieved recently with the launch of Campath.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo